Skip to main content
. 2021 Apr 23;7(17):eabg4038. doi: 10.1126/sciadv.abg4038

Fig. 4. Tumor onset suppression via cRGD-based SeCT therapy in mice.

Fig. 4

(A) Experimental timeline that details the injection schedule of HeLa-Luc cells and the labeling reagents. (B) IVIS imaging results showing a representative set of mice monitored for the onset and progression of HeLa tumors over a period of 4 weeks. (C) Comparison and quantification of bioluminescent signals emitted by HeLa-Luc cancer cells in IVIS imaging of mice (n = 7) over a period of 3 weeks. P values were determined by one-way ANOVA. (D) Comparison of mice survival for various conditions monitored over a period of 81 days. P values were determined using the log-rank test. All numerical data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.